Efficacy of Roflumilast in Bronchiectasis Patients with Frequent Exacerbations: A Double-Blinded, Randomized, Placebo-Controlled Pilot Clinical Trial.

Tuberc Respir Dis (Seoul) · 2022 · PMC8743631 · PMID 34343424

Europe PMC DOI

hedged sentence

0.6100

closest p · 12.2× alpha

0.6100

boldest claim

The sentences

did not reach statistical significancep=0.61not close (p > 0.1)

Body weight losses in the roflumilast and placebo groups were 1.37 kg and 0.77 kg, respectively, but did not reach statistical significance (p=0.61).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.